ADVERTISEMENT

HER2-Targeted Combinations Look Promising

In the NeoSphere study, various combinations of a new HER2-targeted agent called pertuzumab, Herceptin and chemothery were studied in early-stage breast cancer patients with encouraging results.  

BY ELIZABETH WHITTINGTON @eyoste
PUBLISHED THURSDAY, DECEMBER 9, 2010
Talk about this article with other patients, caregivers, and advocates in the Breast CURE discussion group.
When Herceptin (trastuzumab) was approved in 1998, it signaled the beginning of a drug class that targets a specific growth factor, HER2. On Friday morning at the San Antonio Breast Cancer Symposium, researchers presented a phase 2 study that examined various combinations of the investigational HER2-targeted drug pertuzumab in combination with Herceptin and Taxotere (docetaxel) in patients with early-stage, HER2-positive breast cancer. 

In the NeoSphere (Neoadjuvant Study of Pertuzumab and Herceptin in an Early Regimen Evaluation) trial, 417 women were randomized to one of four arms: a combination of pertuzumab and Herceptin with or without Taxotere, Herceptin and Taxotere, or pertuzumab and Taxotere. Upon completion of therapy, all patients underwent surgery and standard treatment of chemotherapy and Herceptin.

Researchers found that 45.8 percent of patients experienced eradication of their tumor when given a combination of pertuzumab, Herceptin and Taxotere, which is statistically significant when compared with the 29 percent found with standard therapy of Herceptin and Taxotere. The pertuzumab and Taxotere group saw a 24 percent eradication of the tumor, also called a pathological complete response.

In patients who received pertuzumab and Herceptin only, 16.8 percent of patients experienced a complete response. This finding led Luca Gianni, MD, director of medical oncology at the National Cancer Institute in Milan, Italy, and lead investigator of the trial, to suggest there might be a subset of patients who would benefit from the combination without chemotherapy. As a next step, researchers are now examining tissue from the study to locate biomarkers that might help identify patients who would benefit from Herceptin and pertuzumab alone, sparing them the side effects of chemotherapy.

Side effects in the trial were not unexpected, and few severe adverse events were seen in the pertuzumab and Herceptin arm. The groups that received Taxotere experienced common side effects associated with the drug, including neutropenia.

In addition, the study design called for neoadjuvant treatment—when drugs are given before surgery to quickly see if they have an effect on the tumor. Traditionally, most drugs are given after surgery to reduce the risk of recurrence, which could occur several years later. Researchers noted that the small trial was remarkable, not only for the results associated with pertuzumab, but also due to the neoadjuvant trial design.

“We strongly believe this neoadjuvant approach allows for rapid testing and ranking of new therapies,” said Gianni during the press conference Friday morning. In addition, researchers are planning a follow-up trial to study the effects of the triple combination given after surgery. 

Talk about this article with other patients, caregivers, and advocates in the Breast CURE discussion group.
ADVERTISEMENT
Related Articles
Telephone Intervention Helps Breast Cancer Survivors Set—and Meet—Lifestyle Goals
BY CHRISTINA IZZO
A new telephone-based intervention for breast cancer survivors is showing promise, and it involves them becoming more actively engaged in goal setting and problem solving with an eye toward accelerating their recovery by engaging in health-promoting activities such as exercise, stress management and healthy eating.
Diabetes May Predispose Women to More Advanced Breast Cancer
BY CHRISTINA IZZO
Breast cancer patients with diabetes were significantly more likely to be diagnosed with advanced-stage breast cancer than those without diabetes.
Crossing Tumor Types: BRCA Experience Points Way to New Diagnostic Paradigm
BY MAURIE MARKMAN, MD
It is now well recognized that the presence of a molecular abnormality shown to be actionable in one tumor type may be highly clinically relevant in other malignancies.
Is Immunotherapy Ready for Prime Time in Breast Cancer?
BY ANDREW D. SMITH
Elizabeth A. Mittendorf, associate professor of surgical oncology at The University of Texas MD Anderson Cancer Center, discusses the progress and potential of immunotherapy in breast cancer treatment.
Angelina Jolie, Knowledge Is Not Enough
Two years ago, Angelina Jolie Pitt told the world that she held the BRCA1 mutation.
Related Videos
Health Advocate Amy Byer Shainman Discusses Risk Management of Hereditary Cancers
When it comes to managing your risk of cancer, especially when dealing with a familial cancer risk, "what is right for one person, may not be right for another," says Amy Byer Shainman.
Research Updates on HER2-Positive Breast Cancer from the 2015 Miami Breast Cancer Conference
Debu Tripathy, editor-in-chief of CURE magazine, discusses updates from the Miami Breast Cancer Conference, including the changing landscape of HER2-positive breast cancer.
Medical Updates from the 32nd Annual Miami Breast Cancer Conference
The evolution of the treatment for hormone receptor-positive breast cancer was a hot topic for this year's Miami Breast Cancer Conference. Debu Tripathy, CURE's editor-in-chief and breast oncologist, reports from the meeting.
Joan Lunden Discusses the Physical and Emotional Effects of Breast Cancer Treatment
Journalist Joan Lunden shares her experience with breast cancer, side effects and working through treatment.
Journalist Joan Lunden Discusses Her Breast Cancer Diagnosis and Treatment
Roy Firestone interviews longtime journalist, author and television host Joan Lunden on her recent breast cancer diagnosis and treatment.
Recent Publications
  • photo
    photo
    photo
    photo
    photo
  • photo
    photo
    photo
    photo
    photo
ADVERTISEMENT
$auto_registration$